Nuchev Pty Ltd · ASX:NUC
Nuchev Pty — FY2026 Earnings Presentation
21 slides from Nuchev Pty's earnings presentation, Aug 27, 2026
Slide 1: FY26 Full Year Results
For personal use only FY26 Full Year Results Year ended 30 June 2026 Building a broader nutrition and wellness platform with the focus now on conversion, margin and cash.
Slide 2: Basis of preparation and disclaimer
IMPORTANT INFORMATION Basis of preparation and disclaimer For personal use only BASIS OF PREPARATION FORWARD-LOOKING STATEMENTS This presentation has been prepared from Nuchev Limited's FY26 audited This presentation may contain forward-looking statements, including consolidated financial statements
Slide 3: Revenue grew; margin, earnings and cash conversion weakened
FY26 HEADLINE RESULT Revenue grew; margin, earnings and cash conversion weakened Domestic growth and the broader distribution platform lifted Group revenue. Lower margin, investment ahead of revenue and For personal use only higher working capital weighed on adjusted EBITDA and cash. The statutory l
Slide 4: Revenue scale has expanded; FY26 disrupted the EBITDA improvement
FIVE-YEAR CONTEXT Revenue scale has expanded; FY26 disrupted the EBITDA improvement Revenue $mils Adjusted EBITDA $mils For personal use only 30 0.0 FY22 FY23 FY24 FY25 FY26 26 25 23 -2.0 20 -4.0 -3.3 -4.6 15 -6.0 -5.9 11 10 -7.4 10 9 -8.0 5 -10.0 -10.2 0 FY22 FY23 FY24 FY25 FY26 -12.0 Revenue incre
Slide 5: Australia drove FY26 growth and became 76% of Group revenue
REVENUE MIX Australia drove FY26 growth and became 76% of Group revenue Revenue $mils For personal use only 30 25 6.3 +37.9% Australia revenue growth 20 8.9 15 10 19.4 –29.3% International revenue change 14.1 5 FY26 international revenue 0 FY25 FY26 China $4.9m | Vietnam $1.4m ANZ International Mix
Slide 6: Gross profit grew 3.2%, but cost of sales grew faster than revenue
GROSS PROFIT Gross profit grew 3.2%, but cost of sales grew faster than revenue For personal use only Revenue $mils Cost of sales $mils Gross profit $mils +12.0% +19.9% +3.2% GROSS MARGIN 25.7 14.5 11.2 22.9 10.9 12.1 47.3% FY25 43.6% FY26 | –3.7pp FY25 FY26 FY25 FY26 FY25 FY26 Drivers disclosed: Ch
Slide 7: FY26 profit and loss — reported result
FINANCIAL SCORECARD FY26 profit and loss — reported result ($mils) For personal use only FY26 FY25 Var Movement % Revenue $25.7 $22.9 +$2.7 +12.0% Gross profit $11.2 $10.9 +$0.3 +3.2% Gross margin 43.6% 47.3% –3.7pp –7.8% Employee benefits expense $(7.4) $(6.1) $(1.3) +20.8% Sales and marketing expe
Slide 8: Adjusted EBITDA loss to statutory loss before tax
NON-IFRS RECONCILIATION Adjusted EBITDA loss to statutory loss before tax ($mils) For personal use only $(4.6) $(0.8) $(1.9) $(0.2) $(7.4) + + + = D&A + inventory Adjusted EBITDA loss Goodwill impairment Net finance costs Loss before tax provision Non-cash goodwill impairment The $1.9m impairment re
Slide 9: Financing supported liquidity as operating cash use increased
CASH FLOW Financing supported liquidity as operating cash use increased ($mils) For personal use only $3.607 $5.267 $2.125 $(0.026) $(6.639) $(0.083) Opening cash Operating Investing Financing FX Closing cash $(6.639)m in FY26 vs $(3.742)m in FY25, reflecting the $5.267m included $1.926m of share pr
Slide 10: The broader distribution model increased balance-sheet intensity
WORKING CAPITAL The broader distribution model increased balance-sheet intensity For personal use only Working capital $mils +96.6% 10 Receivables 9 Distribution activity and customer timing 8 7 increased cash tied up in debtors. +37.3% 6 6 5 Inventory 4 Stock supported a broader portfolio, new 3 3
Slide 11: Available facilities provide flexibility; cash discipline remains essential
LIQUIDITY AND FUNDING Available facilities provide flexibility; cash discipline remains essential For personal use only $6.0m facilities $2.1m $7.6m $5.9m Unsecured shareholder-supported Cash and cash Net current assets Net assets working-capital facilities equivalents $3.5m drawn $2.5m available Go
Slide 12: One integrated nutrition and wellness business across brands & channels
BUSINESS PLATFORM One integrated nutrition and wellness business across brands & channels For personal use only Consumer nutrition Practitioner health Distribution Oli6 BioPractica | Medicine Brauer | Skin Physics | Tree Rapid Loss Established grocery and pharmacy Clinical and practitioner relations
Slide 13: The year expanded the platform and improved domestic momentum
FY26 OPERATING PROGRESS The year expanded the platform and improved domestic momentum For personal use only 01 Oli6 domestic Revenue ahead of FY25 across key grocery and pharmacy customers, supported by established ranging and positive retail momentum. 02 Portfolio expansion Children’s snacking, Nig
Slide 14: International and Practitioner performance remained less consistent
EXECUTION REVIEW International and Practitioner performance remained less consistent For personal use only International Practitioner FY26 revenue was uneven and below expectations. Distributor Performance was stronger early in the year, then softened. Distributor ordering, shipment timing, registra
Slide 15: The platform broadened through the year; momentum improved late
FY26 YEAR IN REVIEW The platform broadened through the year; momentum improved late For personal use only H1 FY26 MARCH 2026 CLOSING MONTHS JUNE 2026 Revenue +12% Distribution transition Brauer contribution Oli6Goat.com live rose 1 2 3 4 Domestic retail and early Brauer, Skin Physics and Rapid Produ
Slide 16: Product and channel activity became more tangible during the year
FY26 PROGRESS Product and channel activity became more tangible during the year For personal use only Consumer nutrition Practitioner health Distribution Oli6 expansion BioPractica Broader distribution ROUTES TO MARKET Grocery Pharmacy Practitioner Digital / DTC China CBEC Vietnam Nuchev Limited | F
Slide 17: Scale the platform, improve contribution and convert growth into cash
STRATEGIC PRIORITIES Scale the platform, improve contribution and convert growth into cash For personal use only 01 02 03 04 05 Strengthen Oli6 Rebuild Scale Commercialise Convert growth Practitioner distribution innovation Build on established Use clinical credibility, Grow Brauer and the Stage sel
Slide 18: Four engines support a broader and more resilient growth profile
GROWTH ENGINES Four engines support a broader and more resilient growth profile For personal use only 01 Oli6 platform Build on domestic retail momentum, extend into adjacent goat nutrition and progress selected international opportunities. 02 Practitioner platform Rebuild the active practitioner ba
Slide 19: How the strategy is intended to convert into profitable growth
STRATEGY CONVERSION How the strategy is intended to convert into profitable growth For personal use only Revenue + Margin + Leverage + Cash = Growth Better Fixed-cost Consistent growth Cash discipline Profitable growth contribution leverage Why the model can scale Nuchev has invested in brands, regu
Slide 20: Execution priorities and planning assumptions, not earnings guidance
FY27 OUTLOOK Execution priorities and planning assumptions, not earnings guidance For personal use only NO FORMAL FY27 EARNINGS GUIDANCE IS PROVIDED PLANNING ASSUMPTIONS — NOT GUIDANCE ACTIONS AVAILABLE IF PERFORMANCE IS BELOW PLAN Continued growth in the domestic retail business Reduce or defer dis
Slide 21: A broader platform. A clear path to profitable growth.
For personal use only A broader platform. A clear path to profitable growth. 1. Proven domestic momentum and a broader revenue base. 2. Multiple brands. Categories and routes to market. 3. Clear focus on contribution, leverage and cash. Investor enquiries